We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » HHS OIG'S PROBES TO INCLUDE CLINICAL STUDIES, MEDICARE Rx CARDS
HHS OIG'S PROBES TO INCLUDE CLINICAL STUDIES, MEDICARE Rx CARDS
October 14, 2004
Determining the extent to which the FDA monitors drugmakers' postmarketing study commitments and evaluating how drug firms compute the average sales price (ASP) for drugs reimbursed under Medicare are among the investigations HHS' Office of Inspector General (OIG) plans to undertake in fiscal 2005.